2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 62

Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 63

Association of Smoking and Cognitive Function in Patients with Fibromyalgia
Abstract Number: 64

Nociceptive Flexion Reflex Threshold: Possible Surrogate Marker of Symptom Severity in Fibromyalgia
Abstract Number: 65

Disability in the Rheumatic Diseases
Abstract Number: 66

Fibromyalgia Patients Identify More Causes of Disease Flare Ups Than RA Patients
Abstract Number: 67

Higher Levels of Pro-Inflammatory and Lower Levels of Anti-Inflammatory Cytokines Are Present in Fibromyalgia Patients
Abstract Number: 68

The Stroop Word-Naming Test in Fibromyalgia Patients
Abstract Number: 69

Fibrofog in Mild and Severe Variants of Fibromyalgia
Abstract Number: 70

Data from Brazilian Fibromyalgia Patients Registry (EPIFIBRO) in 2014
Abstract Number: 71

Fibromyalgia Dysautonomia and Distress. Correlation Between the Newly Developed Composite Autonomic Symptoms (COMPASS-31) Questionnaire and the Fibromyalgia Polysymptomatic Distress Scale
Abstract Number: 72

Performance of the New Survey Criteria for Fibromyalgia Under Conditions of Low and High Symptom Activity
Abstract Number: 73

Anti -N-Methyl-D-Aspartate Receptor Antibody Is Associated with Fibromyalgia in Patients with Systemic Lupus Erythematosus
Abstract Number: 74

Clinical Characteristics of Fibromyalgia in a Chronic Pain Population
Abstract Number: 75

Fibromyalgia and Positional Cervical Cord Compression Differ Only By Autonomic Nervous System Consequences: A Double-Blinded, Prospective Study
Abstract Number: 76

Evaluating Weather’s Effect on Fibromyalgia Patients Using the Revised Fibromyalgia Impact Questionnaire and the Brief Pain Inventory

« Previous Page
1
…
4
5
6
7
8
…
218
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].